JDJudi van Diessen

Judi van Diessen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Judi van Diessen has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improved Overall Survival Due to Reduced Waiting Time in Nasopharyngeal Cancer Patients Treated with Chemoradiotherapy in Yogyakarta, Indonesia

    by Judi Nani Annet Diessen, Ericko Ekaputra, Bing Tan, Sharon Stoker, Camelia Herdini, Wigati Dhamiyati, Retna Dwidanarti, Lidya Meidania, Torana Kurniawan, Seize Yanuarta, et al.

    Background: In Indonesia, nasopharyngeal carcinoma (NPC) is highly prevalent and is one of the leading causes of cancer-related mortality. Lower overall survival (OS), compared to neighboring countries, is associated with a prolonged waiting time (WT) and overall radiotherapy (RT) treatment time (OTT). In 2018, the RT department of the Dr. Sardjito Hospital in Yogyakarta, Indonesia, increased the number of treatment machines and clinical staff. This may have led to an improvements in WT and OTT. Therefore, we analyzed a recent cohort of NPC patients to evaluate the outcomes in light of these changes. Materials and Methods: A retrospective cohort of 229 NPC patients underwent chemoradiotherapy with curative intent between January 2018 and December 2021. The majority had locally advanced NPC. The turning point was in 2018, marking a pivotal year. Consequently, the years 2019-2021 were compared with 2018. Endpoints included WT, OTT, OS, as well as locoregional control (LRC) and disease-free survival (DFS). Results: The mean follow-up time was 16.9 months. For all patients, the median WT and OTT were 110 days and 50 days. Comparing 2018 with 2019-2021, the WT differed significantly with 190 versus 97 days (p<0.001) while the OTT, 53 versus 50 days, was borderline different (p=0.049). The 2-year OS significantly improved from 42.6% in 2018 to 60.5% among patients treated between 2019-2021 (p=0.042). Conclusion: In conclusion, this study analyzed the impact of WT and OTT on outcomes for NPC patients undergoing chemoradiotherapy at Dr. Sardjito Hospital. A significant decrease in WT of 97 days was observed when compared to 2018. However, the limited availability of advanced imaging likely resulted in an underestimation of distant metastases, leading to a 2-yr OS of 60.5%. Better staging methods, as well as improved awareness of NPC, are crucial for better treatment decisions and improving future patient outcomes.

  • The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands

    by Julianne C de Ruiter, David J Heineman, Johannes Ma Daniels, Judi NA van Diessen, Ronald Am Damhuis, Koen J Hartemink


  • Top Cited Papers

    Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols

    by Judith A. E. M. Zecha, Judith E. Raber-Durlacher, Raj G. Nair, Joel B. Epstein, Sharon Elad, Michael R. Hamblin, Andrei Barasch, Cesar A. Migliorati, Dan M. J. Milstein, Marie-Thérèse Genot, et al.

    Purpose There is a large body of evidence supporting the efficacy of low-level laser therapy (LLLT), more recently termed photobiomodulation (PBM) for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved and dosimetric parameters may lead to the management of a broader range of complications associated with HNC treatment. This could enhance patient adherence to cancer therapy, and improve quality of life and treatment outcomes. The mechanisms of action, dosimetric, and safety considerations for PBM have been reviewed in part 1. Part 2 discusses the head and neck treatment side effects for which PBM may prove to be effective. In addition, PBM parameters for each of these complications are suggested and future research directions are discussed. Methods Narrative review and presentation of PBM parameters are based on current evidence and expert opinion. Results PBM may have potential applications in the management of a broad range of side effects of (chemo)radiation therapy (CRT) in patients being treated for HNC. For OM management, optimal PBM parameters identified were as follows: wavelength, typically between 633 and 685 nm or 780–830 nm; energy density, laser or light-emitting diode (LED) output between 10 and 150 mW; dose, 2–3 J (J/cm2), and no more than 6 J/cm2 on the tissue surface treated; treatment schedule, two to three times a week up to daily; emission type, pulsed (route of delivery, intraorally and/or transcutaneously. To facilitate further studies, we propose potentially effective PBM parameters for prophylactic and therapeutic use in supportive care for dermatitis, dysphagia, dry mouth, dysgeusia, trismus, necrosis, lymphedema, and voice/speech alterations. Conclusion PBM may have a role in supportive care for a broad range of complications associated with the treatment of HNC with CRT. The suggested PBM irradiation and dosimetric parameters, which are potentially effective for these complications, are intended to provide guidance for well-designed future studies. It is imperative that such studies include elucidating the effects of PBM on oncology treatment outcomes.


  • Top Cited Papers

    Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations

    by Judith A. E. M. Zecha, Judith E. Raber-Durlacher, Raj G. Nair, Joel B. Epstein, Stephen T. Sonis, Sharon Elad, Michael R. Hamblin, Andrei Barasch, Cesar A. Migliorati, Dan M. J. Milstein, et al.

    Purpose There is a large body of evidence supporting the efficacy of low level laser therapy (LLLT), more recently termed photobiomodulation (PBM), for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved, may expand the applications for PBM in the management of other complications associated with HNC treatment. This article (part 1) describes PBM mechanisms of action, dosimetry, and safety aspects and, in doing so, provides a basis for a companion paper (part 2) which describes the potential breadth of potential applications of PBM in the management of side-effects of (chemo)radiation therapy in patients being treated for HNC and proposes PBM parameters. Methods This study is a narrative non-systematic review. Results We review PBM mechanisms of action and dosimetric considerations. Virtually, all conditions modulated by PBM (e.g., ulceration, inflammation, lymphedema, pain, fibrosis, neurological and muscular injury) are thought to be involved in the pathogenesis of (chemo)radiation therapy-induced complications in patients treated for HNC. The impact of PBM on tumor behavior and tumor response to treatment has been insufficiently studied. In vitro studies assessing the effect of PBM on tumor cells report conflicting results, perhaps attributable to inconsistencies of PBM power and dose. Nonetheless, the biological bases for the broad clinical activities ascribed to PBM have also been noted to be similar to those activities and pathways associated with negative tumor behaviors and impeded response to treatment. While there are no anecdotal descriptions of poor tumor outcomes in patients treated with PBM, confirming its neutrality with respect to cancer responsiveness is a critical priority. Conclusion Based on its therapeutic effects, PBM may have utility in a broad range of oral, oropharyngeal, facial, and neck complications of HNC treatment. Although evidence suggests that PBM using LLLT is safe in HNC patients, more research is imperative and vigilance remains warranted to detect any potential adverse effects of PBM on cancer treatment outcomes and survival.


  • Open Access

    Nephrotoxicity as a Dose-Limiting Factor in a High-Dose Cisplatin-Based Chemoradiotherapy Regimen for Head and Neck Carcinomas

    by Jantien Hoek, Karen M. Bloemendal, Lilly-Ann A. Van der Velden, Judi N.A. Van Diessen, Erik Van Werkhoven, Willem M.C. Klop, Margot E.T. Tesselaar

    Purpose: Loco-regional control and organ preservation are significantly improved with concomitant cisplatin/radiotherapy and are compromised with less than 5% grade 3 nephrotoxicity (creatinine clearance 15–29 mL/min). However, although clinically important, in none of the randomized trials is grade 2 nephrotoxicity (defined as creatinine clearance 59–30 mL/min) mentioned. In this study, we assessed nephrotoxicity in daily practice among patients treated with high-dose cisplatin (100 mg/m2 on days 1, 22, and 43), concurrently with chemoradiotherapy (CCRT) and the impact on treatment modifications. Methods: 208 patients with advanced-stage malignancies of the head and neck region were evaluated. All patients were treated with high-dose cisplatin CCRT. The main outcome parameters were nephrotoxicity (defined as creatinine clearance grade 2 or more) and cumulative doses of cisplatin and radiation. Results: 133 patients (64%) completed all pre-planned courses of cisplatin. Nephrotoxicity was the main reason to discontinue the chemotherapy. Grade 3 nephrotoxicity was seen in 16 patients (8%) while grade 2 nephrotoxicity was seen in 53 patients (25%). Thirty six patients (17%) could not complete the pre-planned chemotherapy due to nephrotoxicity. Conclusions: In head and neck cancer patients, nephrotoxicity grade 2 is under-reported but is the major factor for discontinuing cisplatin during CCRT.


  • Open Access

    Current Treatment Options for Local Residual Nasopharyngeal Carcinoma

    by S. D. Stoker, J. N. A. van Diessen, J. P. de Boer, B. Karakullukcu, C. R. Leemans, I. B. Tan